One of the underlying mechanisms was the upregulation of FAS/FASL and PD-1/PD-L2 on CD8+ T cells and CAFs, respectively, which drives the dysfunction of tumor-specific CD8+ T cells (Lakins et al., 2018). Here, CD8A is linked to neoplasm.